Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 17;10(10):e005815. doi: 10.1136/jitc-2022-005815

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Clinical case presentation of IgE type multiple myeloma. (A) MRI (T1 and DWI) and CT imaging of osteolytic lesions in pelvic bone and cervical spine (highlighted in red). (B) Serological activity parameters (IgE in IU/L, serum free kappa light chains (sFLC) and urine free kappa light chains (uFLC) in mg/l) over course of disease. (C) Histopathological features of bone marrow biopsy at disease relapse. Immunohistochemistry stains indicated in-figure. (D) Flow cytometry quantification of aberrant markers and expression of potential therapeutic targets on malignant IgE type MM cells in bone marrow aspirate at relapse. (E) Cytogenetic analysis by iFISH identifies IgH rearrangement in form of t(11;14). (F) Flow cytometry-based assessment and quantification of bone marrow-associated CD4⁺ and CD8⁺ T cells and respective programmed cell death protein 1 (PD-1) surface expression on CD4⁺ and CD8⁺ T cell subsets. MM, multiple myeloma. DWI, diffusion weighted imaging.